The increasing knowledge of barrier tissue-resident memory macrophages and trained innate immunity (TII) will help develop both nontarget-specific and target-specific TII-based vaccine strategies.
STAT Wunderkind Sydney Ramirez is revealing the immune system in our nasal passages and working toward better disease ...
Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed ...
The poster for INSIGHT-003 and the Trial in Progress ePoster for TACTI-004 can be found at the Posters & Publications section of Immutep’s website.
The statements regarding Herpafend have not been evaluated by the Food and Drug Administration (FDA). This product is not ...
Background:Respiratory viruses, including influenza viruses, respiratory syncytial virus (RSV), coronaviruses, and other emerging zoonotic pathogens, remain ...
Company completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq complianceSOUTH SAN FRANCISCO, Calif., Oct.
Presentations highlight HCB101's differentiated profile and introduce first preclinical data from HCB301, underscoring HanchorBio's innovation in ...
Light Chain Bioscience, a clinical-stage biotechnology company advancing the next generation of bispecific antibodies to treat cancer, today presented positive results from a Phase 1/1b study of ...
HanchorBio today announced that its proprietary HCB101, a SIRPa/CD47 fusion protein candidate, has been officially granted a US patent (Patent No.
For me, there are two main takeaways from the study. The first is that we still don't take CSU seriously enough. It is a ...
Eikon Therapeutics, Inc., a late-stage clinical biopharmaceutical company dedicated to integrating advanced engineering with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback